Boundless Bio to Present at the Guggenheim Oncology Conference

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Executive Officer, Zachary Hornby, will present at the Guggenheim Oncology Conference, which will take place virtually. Presentation details are as follows:

Date: Friday, February 11, 2022

Time: 2:00 PM – 2:25 PM EST

About Boundless Bio

Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

For more information, visit www.boundlessbio.com.

Follow us on LinkedIn and Twitter.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  268.84
-3.43 (-1.26%)
AAPL  302.11
-2.80 (-0.92%)
AMD  487.04
+12.72 (2.68%)
BAC  64.58
+0.58 (0.91%)
GOOG  341.57
-1.43 (-0.42%)
META  581.71
-17.41 (-2.91%)
MSFT  493.47
-10.34 (-2.05%)
NVDA  224.04
+6.54 (3.01%)
ORCL  153.28
+7.80 (5.36%)
TSLA  325.96
-6.85 (-2.06%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.